{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:21:17Z","timestamp":1787509277640,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10147-025-02732-2","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T07:54:27Z","timestamp":1741420467000},"page":"904-913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study"],"prefix":"10.1007","volume":"30","author":[{"given":"Yuriko","family":"Ishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-7911","authenticated-orcid":false,"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiki","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae","family":"Iwasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"2732_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G De Velasco","year":"2017","unstructured":"De Velasco G, Je Y, Boss\u00e9 D et al (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5:312\u2013318. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0237","journal-title":"Cancer Immunol Res"},{"key":"2732_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"2732_CR3","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","volume":"15","author":"Y Suzuki","year":"2020","unstructured":"Suzuki Y, Karayama M, Uto T et al (2020) Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study. J Thorac Oncol 15:1317\u20131327. https:\/\/doi.org\/10.1016\/j.jtho.2020.04.002","journal-title":"J Thorac Oncol"},{"key":"2732_CR4","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","volume":"13","author":"K Suresh","year":"2018","unstructured":"Suresh K, Voong KR, Shankar B et al (2018) Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol 13:1930\u20131939. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2035","journal-title":"J Thorac Oncol"},{"key":"2732_CR5","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST","volume":"200","author":"CR Sears","year":"2019","unstructured":"Sears CR, Peikert T, Possick JD et al (2019) Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An official American Thoracic Society research statement. Am J Respir Crit Care Med 200:e31\u2013e43. https:\/\/doi.org\/10.1164\/rccm.201906-1202ST","journal-title":"Am J Respir Crit Care Med"},{"key":"2732_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1759-7714.12759","volume":"9","author":"O Kanai","year":"2018","unstructured":"Kanai O, Kim YH, Demura Y et al (2018) Efficacy and safety of nivolumab in non-small cell lung cancer with pre-existing interstitial lung disease. Thorac Cancer 9:847\u2013855. https:\/\/doi.org\/10.1111\/1759-7714.12759","journal-title":"Thorac Cancer"},{"key":"2732_CR7","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H et al (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2:1607\u20131616. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2453","journal-title":"JAMA Oncol"},{"key":"2732_CR8","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","volume":"154","author":"K Suresh","year":"2018","unstructured":"Suresh K, Naidoo J, Lin CT et al (2018) Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest 154:1416\u20131423. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1048","journal-title":"Chest"},{"key":"2732_CR9","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1002\/cam4.1579","volume":"7","author":"P Cui","year":"2018","unstructured":"Cui P, Liu Z, Wang G et al (2018) Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case\u2013control study. Cancer Med 7:4115\u20134120. https:\/\/doi.org\/10.1002\/cam4.1579","journal-title":"Cancer Med"},{"key":"2732_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","volume":"69","author":"R Shibaki","year":"2020","unstructured":"Shibaki R, Murakami S, Matsumoto Y et al (2020) Association of immune-related pneumonitis with the presence of pre-existing interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother 69:15\u201322. https:\/\/doi.org\/10.1007\/s00262-019-02431-8","journal-title":"Cancer Immunol Immunother"},{"key":"2732_CR11","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1111\/cas.15117","volume":"112","author":"N Yamamoto","year":"2021","unstructured":"Yamamoto N, Nakanishi Y, Gemma A et al (2021) Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: postmarketing surveillance. Cancer Sci 112:4692\u20134701. https:\/\/doi.org\/10.1111\/cas.15117","journal-title":"Cancer Sci"},{"issue":"5","key":"2732_CR12","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44\u2013e68","journal-title":"Am J Respir Crit Care Med"},{"key":"2732_CR13","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1111\/cas.14217","volume":"110","author":"H Kenmotsu","year":"2019","unstructured":"Kenmotsu H, Yoh K, Mori K et al (2019) Phase II study of nab-paclitaxel+carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. Cancer Sci 110:3738\u20133745. https:\/\/doi.org\/10.1111\/cas.14217","journal-title":"Cancer Sci"},{"key":"2732_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2019.09.020","volume":"138","author":"H Asahina","year":"2019","unstructured":"Asahina H, Oizumi S, Takamura K et al (2019) A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). Lung Cancer 138:65\u201371. https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.020","journal-title":"Lung Cancer"},{"key":"2732_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00280-015-2775-y","volume":"76","author":"N Watanabe","year":"2015","unstructured":"Watanabe N, Niho S, Kirita K et al (2015) Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother Pharmacol 76:69\u201374. https:\/\/doi.org\/10.1007\/s00280-015-2775-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"2732_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/1471-2407-14-508","volume":"14","author":"M Kato","year":"2014","unstructured":"Kato M, Shukuya T, Takahashi F et al (2014) Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer 14:508. https:\/\/doi.org\/10.1186\/1471-2407-14-508","journal-title":"BMC Cancer"},{"key":"2732_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","volume":"111","author":"D Fujimoto","year":"2017","unstructured":"Fujimoto D, Morimoto T, Ito J et al (2017) A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer 111:1\u20135. https:\/\/doi.org\/10.1016\/j.lungcan.2017.06.008","journal-title":"Lung Cancer"},{"key":"2732_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.lungcan.2019.06.001","volume":"134","author":"D Fujimoto","year":"2019","unstructured":"Fujimoto D, Yomota M, Sekine A et al (2019) Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: a multicenter, open-label single-arm phase II trial. Lung Cancer 134:274\u2013278. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.001","journal-title":"Lung Cancer"},{"key":"2732_CR19","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jtho.2020.08.018","volume":"15","author":"S Ikeda","year":"2020","unstructured":"Ikeda S, Kato T, Kenmotsu H et al (2020) A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis. J Thorac Oncol 15:1935\u20131942. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.018","journal-title":"J Thorac Oncol"},{"key":"2732_CR20","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.chest.2021.12.656","volume":"161","author":"M Zhang","year":"2022","unstructured":"Zhang M, Fan Y, Nie L et al (2022) Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and pre-existing interstitial lung diseases: a systematic review and meta-analysis. Chest 161:1675\u20131686. https:\/\/doi.org\/10.1016\/j.chest.2021.12.656","journal-title":"Chest"},{"key":"2732_CR21","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 205:e18\u2013e47. https:\/\/doi.org\/10.1164\/rccm.202202-0399ST","journal-title":"Am J Respir Crit Care Med"},{"key":"2732_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","volume":"51","author":"K Kubo","year":"2013","unstructured":"Kubo K, Azuma A, Kanazawa M et al (2013) Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51:260\u2013277. https:\/\/doi.org\/10.1016\/j.resinv.2013.09.001","journal-title":"Respir Investig"},{"key":"2732_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2021.03.014","volume":"155","author":"Y Tasaka","year":"2021","unstructured":"Tasaka Y, Honda T, Nishiyama N et al (2021) Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer 155:120\u2013126. https:\/\/doi.org\/10.1016\/j.lungcan.2021.03.014","journal-title":"Lung Cancer"},{"key":"2732_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s10147-019-01576-x","volume":"25","author":"N Nishiyama","year":"2020","unstructured":"Nishiyama N, Honda T, Sema M et al (2020) The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease. Int J Clin Oncol 25:282\u2013291. https:\/\/doi.org\/10.1007\/s10147-019-01576-x","journal-title":"Int J Clin Oncol"},{"key":"2732_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.resinv.2015.06.001","volume":"53","author":"T Ogura","year":"2015","unstructured":"Ogura T, Azuma A, Inoue Y et al (2015) All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig 53:232\u2013241. https:\/\/doi.org\/10.1016\/j.resinv.2015.06.001","journal-title":"Respir Investig"},{"key":"2732_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S2213-2600(16)30033-9","volume":"4","author":"SLF Walsh","year":"2016","unstructured":"Walsh SLF, Wells AU, Desai SR et al (2016) Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 4:557\u2013565. https:\/\/doi.org\/10.1016\/S2213-2600(16)30033-9","journal-title":"Lancet Respir Med"},{"key":"2732_CR27","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s11547-016-0627-4","volume":"121","author":"F Ciccarese","year":"2016","unstructured":"Ciccarese F, Attin\u00e0 D, Zompatori M (2016) Combined pulmonary fibrosis and emphysema (CPFE): what radiologist should know. Radiol Med 121:564\u2013572. https:\/\/doi.org\/10.1007\/s11547-016-0627-4","journal-title":"Radiol Med"},{"key":"2732_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","volume":"193","author":"U Costabel","year":"2016","unstructured":"Costabel U, Inoue Y, Richeldi L et al (2016) Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 193:178\u2013185. https:\/\/doi.org\/10.1164\/rccm.201503-0562OC","journal-title":"Am J Respir Crit Care Med"},{"key":"2732_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lungcan.2016.03.017","volume":"96","author":"Y Enomoto","year":"2016","unstructured":"Enomoto Y, Inui N, Kato T et al (2016) Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Lung Cancer 96:63\u201367. https:\/\/doi.org\/10.1016\/j.lungcan.2016.03.017","journal-title":"Lung Cancer"},{"key":"2732_CR30","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/medicina55090580","volume":"55","author":"DE Amariei","year":"2019","unstructured":"Amariei DE, Dodia N, Deepak J et al (2019) Combined pulmonary fibrosis and emphysema: pulmonary function testing and a pathophysiology perspective. Medicina (Kaunas) 55:580. https:\/\/doi.org\/10.3390\/medicina55090580","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"2732_CR31","first-page":"00981","volume":"10","author":"K Isobe","year":"2014","unstructured":"Isobe K, Nakamura Y, Sakamoto S et al (2014) Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia. ERJ Open Res 10(2):00981","journal-title":"ERJ Open Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02732-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T02:04:26Z","timestamp":1745287466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02732-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2732"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02732-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Satoshi Ikeda received honoraria from AstraZeneca, Bristol Myers Squibb, Ono, Taiho, Chugai, Boehringer Ingelheim, Eli Lilly, Takeda, Pfizer, MSD, Amgen, and Novartis; research funding from AstraZeneca and Chugai; and took on a consulting or advisory roles for AstraZeneca, Chugai and Daiichi Sankyo. Yuriko Ishida, Toshiyuki Harada, Jun Sakakibara-Konishi, and Hajime Kikuchi, have no conflicts of interest to declare. Keiki Yokoo received honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan K.K., Merck Serono, MSD K.K., NIPPON KAYAKU, Takeda Pharmaceutical Co. Ltd. Toshihiro Misumi received honoraria from AstraZeneca, Chugai, and Miyarisan. Tae Iwasawa received honoraria from Astellas Pharma, Toray Industries, Chugai, Eisai, Japanese Boehringer Ingelheim, Shionogi & Co., Ltd; and participated on a Data Safety Monitoring Board or Advisory Board to Bristol Myers Squibb, Japanese Boehringer Ingelheim, Taiho Pharmaceutical Co., Ltd. Satoshi Konno received research funding from Chugai Pharmaceutical. Takashi Ogura received honoraria from Astellas Pharma, Chugai, Eisai, Japanese Boehringer Ingelheim, Shionogi & Co., Ltd., Toray industries; and participated on a Data Safety Monitoring Board or Advisory Board to Bristol Myers Squibb, Japanese Boehringer Ingelheim, Taiho Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}